Travere Therapeutics (TVTX) Non-Current Assets (2013 - 2026)
Travere Therapeutics posted quarterly Non-Current Assets of $162.5 million for Q1 2026, down 6.94% year-on-year from $174.6 million in Q1 2025, and down 3.05% on a QoQ basis from $167.6 million in Q4 2025.
Travere Therapeutics (TVTX) has 14 years of Non-Current Assets data on file, last reported at $162.5 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 6.94% year-over-year to $162.5 million; the trailing twelve-month figure through Mar 2026 stood at $673.3 million (down 5.68% YoY), and the FY2025 full-year result was $167.6 million, down 5.52% from the prior year.
- Non-Current Assets for Q1 2026 stood at $162.5 million, down from $167.6 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $203.3 million in Q1 2023 and bottomed at $146.6 million in Q3 2023.
- The 5-year median for Non-Current Assets is $179.7 million (2024), against an average of $179.6 million.
- The widest annual swing landed in 2023, when Non-Current Assets fell 23.39%; it then increased 22.54% in 2024.
- A 5-year view of Non-Current Assets shows it stood at $186.1 million in 2022, then fell by 7.53% to $172.1 million in 2023, then climbed by 3.07% to $177.4 million in 2024, then fell by 5.52% to $167.6 million in 2025, then declined by 3.05% to $162.5 million in 2026.
- The last three Non-Current Assets figures came in at $162.5 million (Q1 2026), $167.6 million (Q4 2025), and $167.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Travere Therapeutics | 4.14 Bn | 4.06 Bn | 102.38 Mn | 162.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 162.51 Mn |
| Dec 31, 2025 | 167.63 Mn |
| Sep 30, 2025 | 167.47 Mn |
| Jun 30, 2025 | 175.74 Mn |
| Mar 31, 2025 | 174.63 Mn |
| Dec 31, 2024 | 177.42 Mn |
| Sep 30, 2024 | 179.67 Mn |
| Jun 30, 2024 | 182.14 Mn |
| Mar 31, 2024 | 182.47 Mn |
| Dec 31, 2023 | 172.14 Mn |
| Sep 30, 2023 | 146.62 Mn |
| Jun 30, 2023 | 194.37 Mn |
| Mar 31, 2023 | 203.33 Mn |
| Dec 31, 2022 | 186.15 Mn |
| Sep 30, 2022 | 191.37 Mn |
| Jun 30, 2022 | 192.72 Mn |
| Mar 31, 2022 | 197.31 Mn |
| Dec 31, 2021 | 193.81 Mn |
| Sep 30, 2021 | 196.00 Mn |
| Jun 30, 2021 | 196.97 Mn |
| Mar 31, 2021 | 199.01 Mn |
| Dec 31, 2020 | 197.03 Mn |
| Sep 30, 2020 | 194.54 Mn |
| Jun 30, 2020 | 173.13 Mn |
| Mar 31, 2020 | 166.43 Mn |
| Dec 31, 2019 | 175.74 Mn |
| Sep 30, 2019 | 174.10 Mn |
| Jun 30, 2019 | 190.56 Mn |
| Mar 31, 2019 | 192.16 Mn |
| Dec 31, 2018 | 213.48 Mn |
| Sep 30, 2018 | 213.20 Mn |
| Jun 30, 2018 | 212.23 Mn |
| Mar 31, 2018 | 213.99 Mn |
| Dec 31, 2017 | 194.54 Mn |
| Sep 30, 2017 | 195.17 Mn |
| Jun 30, 2017 | 187.47 Mn |
| Mar 31, 2017 | 187.98 Mn |
| Dec 31, 2016 | 192.93 Mn |
| Sep 30, 2016 | 189.83 Mn |
| Jun 30, 2016 | 233.81 Mn |
| Mar 31, 2016 | 209.36 Mn |
| Dec 31, 2015 | 210.33 Mn |
| Sep 30, 2015 | 211.68 Mn |
| Jun 30, 2015 | 180.40 Mn |
| Mar 31, 2015 | 182.45 Mn |
| Dec 31, 2014 | 98.14 Mn |
| Sep 30, 2014 | 100.49 Mn |
| Dec 31, 2013 | 13.00 Mn |
| Sep 30, 2013 | 4.52 Mn |
| Mar 31, 2013 | 2.31 Mn |